Roche

FY Revenues: $49.8 billion (+1%)

FY Earnings: $10.7 billion (+5%)

Comments: Pharmaceutical Division sales were $38.6 billion, up 2%. MabThera/Rituxan sales were $7.3 billion (+9% in local currencies). Herceptin sales were $6.4 billion (+11% lc). Avastin sales were $6.3 billion (+6% lc). Diagnostics Division revenues were flat at $11.2 million. R&D spend was $8.2 billion, up 2%.